(Abst.) Alemtuzumab-induced lung injury in 3 MS patients on: November 03, 2019, 07:27:43 pm #1 From PubMed (November 2, 2019), "Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients": Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients - PubMed Clinicians should be aware to early recognize acute and subacute respiratory adverse events for a promptly management. In these patients re-treatment is challenging. PubMed · ncbi.nlm.nih.gov Logged MS Speaks--online for 20 yearsSPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) 12/16/20 - 3/16/24.
